Hemodynamic effects of ambrisentan-tadalafil combination therapy on progressive portopulmonary hypertension  

作　　者：Yu Yamashita Ichizo Tsujino Takahiro Sato Asuka Yamada Taku Watanabe Hiroshi Ohira Masaharu Nishimura 

机构地区：[1]First Department of Medicine, Hokkaido University Hospital

出　　处：《World Journal of Hepatology》2014年第11期825-829,共5页世界肝病学杂志（英文版）（电子版）

摘　　要：Intravenous epoprostenol is recommended for World Health Organization functional class(WHO-FC) Ⅳ patients with pulmonary arterial hypertension(PAH) in the latest guidelines. However, in portopulmonary hypertension(PoP H) patients, advanced liver dysfunction and/or thrombocytopenia often makes the use of intravenous epoprostenol challenging. Here we report the cases of two WHO-FC Ⅳ PoP H patients who were successfully treated with a combination of two oral vasodilators used to treat PAH: ambrisentan and tadalafil. Oral vasodilator therapy using a combination of ambrisentan and tadalafil may be a safe and effective therapeutic option for WHO-FC Ⅳ PoP H patients and should be considered for selected patients with severe and rapidly progressing PoP H.Intravenous epoprostenol is recommended for World Health Organization functional class(WHO-FC) Ⅳ patients with pulmonary arterial hypertension(PAH) in the latest guidelines. However, in portopulmonary hypertension(PoP H) patients, advanced liver dysfunction and/or thrombocytopenia often makes the use of intravenous epoprostenol challenging. Here we report the cases of two WHO-FC Ⅳ PoP H patients who were successfully treated with a combination of two oral vasodilators used to treat PAH: ambrisentan and tadalafil. Oral vasodilator therapy using a combination of ambrisentan and tadalafil may be a safe and effective therapeutic option for WHO-FC Ⅳ PoP H patients and should be considered for selected patients with severe and rapidly progressing PoP H.

关 键 词：Portopulmonary hypertension AMBRISENTAN TADALAFIL THROMBOCYTOPENIA 

分 类 号：R544.1[医药卫生—心血管疾病]